The parent company of RetinAI U.S., Ikerian AG, located in Bern, Switzerland, has secured USD 6.18 million in Series A extension investment. Ikerian AG develops software solutions for medical imaging and data management, as well as artificial intelligence (AI) in healthcare.
Investors
- Topcon Healthcare
- Inc.’s corporate venture capital division led the financing
- Zürcher Kantonalbank (ZKB) joined the current Seed and Series A venture companies
- Matterwave Ventures
- Verve Ventures
- private investors in the btov Industrial Technologies
With the Seed and Series A rounds combined, the total equity raised now stands at USD 11.66M (CHF 10.66M) thanks to this Series A Extension.
The money will be used by the business to support RetinAI Discovery®’s growth into new therapeutic areas, with a focus on neurodegenerative illnesses, vascular problems, and rare diseases, as well as its ongoing research and commercial launch in ophthalmology and optometry.
RetinAI Medical AG, rebranded as Ikerian AG, and its wholly-owned subsidiary RetinAI U.S. Inc., which is focused on the ophthalmology market, are the company’s flagship developments beyond ophthalmology. The corporate restructuring was completed as part of the financing and to support the company’s evolution and growth. It began in 2023.
Ikerian AG, formerly known as RetinAI Medical AG, and its subsidiary RetinAI U.S. are led by CEO Dr. Carlos Ciller. They offer software solutions that use sophisticated machine learning and computer vision to speed clinical, research, and pharmaceutical operations internationally.
“The successful closing of this financing confirms the importance of our AI technology to re-invent workflows for clinical and pharmaceutical research to support more efficient and effective patient care. These funding will enable us to work with Topcon Healthcare and the industry to advance AI in ophthalmology and beyond, as well as to accelerate the development of our RetinAI Discovery® platform and our pipeline of AI technologies.”
CEO Dr. Carlos Ciller
With a focus on the ophthalmology and optometry markets, RetinAI creates tools to gather, arrange, and evaluate health information from the eyes, empowering medical practitioners to make informed choices more quickly. For serious eye illnesses, its multinational team uses its clinical, technological, and scientific capabilities to support the shift from reactive to preventative treatment.
